Atopic Dermatitis | AbbVie | M16-046
Pharmaceutical Company/Sponsor:
AbbVie
Code:
M16-046
Title:
A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis.
Type:
Interventional
Phase:
3b
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Drug: Upadacitinib (ABT-494)
Drug: Dupilumab
Drug: Placebo
Status:
Completed
Link for Additional Information:
